prmt-5-in-2

PRMT5-IN-2 is an inhibitor of protein arginine methyltransferase 5.

Prmt5-IN-20 chloride is a potent protein arginine methyltransferase 5 (PRMT5) inhibitor. It strongly disrupts the activation of oncogenic transcriptional programs by blocking the symmetric dimethylation of histone and non-histone proteins, exhibiting outstanding anti-proliferative activity in various hematological and solid tumor models.

BLL5 Maleate (PRMT5-IN-20) is a selective PRMT5 inhibitor that blocks EBV-driven B-cell transformation and survival without affecting normal B cells.

PRMT5-IN-21 (compound 1) is a potent inhibitor of the cyclonucleoside enzyme PRMT5.

PRMT5-IN-22 (compound 53), an inhibitor of protein arginine methyltransferase 5 (PRMT5), exhibits anti-tumor activity. As a protein arginine methyltransferase, PRMT5 represents a novel anti-tumor target associated with epigenetic modification [1].

PRMT5-IN-23 (compound 50), an inhibitor of protein arginine methyltransferase 5 (PRMT5), exhibits anti-tumor activity. As a novel anti-tumor target associated with epigenetic modification, PRMT5 belongs to the protein arginine methyltransferase family [1].

PRMT5-IN-25 (compound 503) is a potent PRMT5 inhibitor with an inhibition constant (K i) of 0.06 nM and demonstrated antiproliferative properties [1].

PRMT5-IN-29 is a potent, orally active inhibitor of PRMT5, exhibiting an IC50 value of 1.5 μM, showing promise for use in advanced cancer research [1].

PRMT5-IN-28 (compound 36) serves as an inhibitor of the protein arginine methyltransferase 5 (PRMT5) enzyme, which is involved in gene transcription, mRNA splicing, DNA repair, protein localization, cell fate determination, and signal transduction. Dysregulated PRMT5 activity contributes to oncogenesis by promoting cancer cell proliferation, apoptosis resistance, invasion, metastasis, and impacting immune evasion [1].